type 2 diabetes semaglutide diabetes: Ozempic and Wegovy improve blood sugar, weight loss Oral "ozempic" lowers A1c and

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation

We are proud to offer both surgical and nonsurgical medical weight management approaches to weight loss

Injection sites Thigh, abdomen (at least 2 inches from navel), or upper arm

Not peptides, but commonly offered alongside them Under FDA review BPC-157, TB-500, KPV, MOTS-C on the July 2026 agenda DSIP, Semax, Epitalon on the July 2026 agenda GHK-Cu second review by Feb 2027 CJC-1295 and Ipamorelin were declined in 2024 and remain restricted, not coming back via this process